回顾性分析紫杉醇联合表柔比星新辅助化疗方案治疗三阴性乳腺癌的疗效

Retrospective analysis the effecte of anthracyclines neoadjuvant chemotherapy regimen on the patients with triple negative breast cancer treated

目的回顾性分析紫杉醇联合表柔比星新辅助化疗方案治疗三阴性乳腺癌(TNBC)的疗效。方法术前行4个周期紫杉联合表柔比星新辅助化疗方案治疗的乳腺癌患者151例,依据用药情况,47例作为TNBC组,104例作为对照组。比较2组患者反应率及术后远期疗效。结果 2组客观反应率差别无统计学意义(P>0.05);病理完全缓解,TNBC组显著高于对照组(34 vs 16,P<0.05)。2组随访期间死亡患者分别为34,13,但死亡风险无明显差别(HR=1.39,P>0.05)。结论 TNBC组患者更易从新辅助化疗中获完全缓解;但2组远期疗效无明显差别。

Objective To analyze the effecte of taxanes and anthracyclines neoadjuvant chemotherapy regimen（TANCR） on the patients with triple negative breast cancer（TNBC）.Methods One hundred and fifty one patients of breast cancer treated with taxanes and anthracyclines neoadjuvant chemotherapy regimen were involved.Forty-seven patients were in the TNBC group,and 104 in control group.The long-term prognosis and response for patients with TNBC treated with TANCR was analyzed between the two groups.Results The overall objective response（OR） was 81.5%（123/1151）,which demonstrated no statistical difference of OR between the two groups（P 0.05）.The pathology complete response in TNBC group had superior than in control group（34 vs 16,P 0.05）.And no statistical difference of survival hazard ratio（HR） between the two groups was detected（HR = 1.39,P = 0.41）.Conclusion The patients in the TNBC group seem to be easily got complete response than in control group.But there was not significant difference on the long-term prognosis in two groups.